EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models

Elizabeth Gray iD, Michelle Ulrich, Angela Epp, Patrick Younan, Disha Sahetya, Kelly Hensley, Sean Allred, Li-Ya Huang, Julie Hahn, Kristen Gahnberg, Piper M Treuting, Esther S Trueblood und 13 weitere

Journal for ImmunoTherapy of Cancer · 2023

DOI: 10.1136/jitc-2023-007572 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2023. Verfasst von Elizabeth Gray und 24 weiteren Autor:innen. Beteiligte Einrichtung: Seagen Inc, Bothell, Washington, USA egray@seagen.com. Hauptthemen laut MEDLINE: Antineoplastic Agents, Immunoconjugates. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Seagen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

SGN-B7H4V is a novel investigational vedotin antibody–drug conjugate (ADC) comprising a B7-H4-directed human monoclonal antibody conjugated to the cytotoxic payload monomethyl auristatin E (MMAE) via a protease-cleavable maleimidocaproyl valine citrulline (mc-vc) linker. This vedotin linker-payload system has been clinically validated in multiple Food and Drug Administration approved agents including brentuximab vedotin, enfortumab vedotin, and tisotumab vedotin. B7-H4 is an immune checkpoint ligand with elevated expression on a variety of solid tumors, including breast, ovarian, and endometrial tumors, and limited normal tissue expression. SGN-B7H4V is designed to induce direct cytotoxicity against target cells by binding to B7-H4 on the surface of target cells and releasing the cytotoxic payload MMAE upon internalization of the B7-H4/ADC complex.

Methods

B7-H4 expression was characterized by immunohistochemistry across multiple solid tumor types. The ability of SGN-B7H4V to kill B7-H4-expressing tumor cells in vitro and in vivo in a variety of xenograft tumor models was also evaluated. Finally, the antitumor activity of SGN-B7H4V as monotherapy and in combination with an anti-programmed cell death-1 (PD-1) agent was evaluated using an immunocompetent murine B7-H4-expressing Renca tumor model.

Results

Immunohistochemistry confirmed B7-H4 expression across multiple solid tumors, with the highest prevalence in breast, endometrial, and ovarian tumors. In vitro, SGN-B7H4V killed B7-H4-expressing tumor cells by MMAE-mediated direct cytotoxicity and antibody-mediated effector functions including antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis. In vivo, SGN-B7H4V demonstrated strong antitumor activity in multiple xenograft models of breast and ovarian cancer, including xenograft tumors with heterogeneous B7-H4 expression, consistent with the ability of vedotin ADCs to elicit a bystander effect. In an immunocompetent murine B7-H4-expressing tumor model, SGN-B7H4V drove robust antitumor activity as a monotherapy that was enhanced when combined with an anti-PD-1 agent.

Conclusion

The immune checkpoint ligand B7-H4 is a promising molecular target expressed by multiple solid tumors. SGN-B7H4V demonstrates robust antitumor activity in preclinical models through multiple potential mechanisms. Altogether, these preclinical data support the evaluation of SGN-B7H4V as a monotherapy in the ongoing phase 1 study of SGN-B7H4V in advanced solid tumors ( NCT05194072 ) and potential future clinical combinations with immunotherapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsImmunoconjugatesAnimalsHumansMiceCell Line, TumorDisease Models, AnimalImmunohistochemistryLigands

Stichwörter der Autor:innen

Drug Evaluation, PreclinicalDrug Therapy, CombinationTherapies, InvestigationalTranslational Medical ResearchTumor Microenvironment

Substanzen

Antineoplastic AgentsImmunoconjugatesLigands

Autor:innen und Institutionen

  • Seagen Inc, Bothell, Washington, USA egray@seagen.com.
  • Seagen Inc, Bothell, Washington, USA.

ORCID-Profile: Elizabeth Gray

Förderung

  • Seagen

Zitieren

APA

Gray, E., Ulrich, M., Epp, A., Younan, P., Sahetya, D., Hensley, K., Allred, S., Huang, L. Y., Hahn, J., Gahnberg, K., Treuting, P. M., Trueblood, E. S., Gosink, J. J., Thurman, R., Wo, S., Spahr, K., Haass, E. J., Snead, K., Miller, D., …, & Gardai, S. J. (2023). SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2023-007572

Vancouver

Gray E, Ulrich M, Epp A, Younan P, Sahetya D, Hensley K, et al. SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models. Journal for ImmunoTherapy of Cancer. 2023. doi:10.1136/jitc-2023-007572

BibTeX
@article{Gray2023,
  author = {Gray, Elizabeth and Ulrich, Michelle and Epp, Angela and Younan, Patrick and Sahetya, Disha and Hensley, Kelly and Allred, Sean and Huang, Li-Ya and Hahn, Julie and Gahnberg, Kristen and Treuting, Piper M and Trueblood, Esther S and Gosink, John J and Thurman, Robert and Wo, Serena and Spahr, Kellie and Haass, Evgenia Jane and Snead, Katie and Miller, Dannah and Padilla, Mary and Smith, Alyson J and Frantz, Chris and Schrum, Jason P and Nazarenko, Natalya and Gardai, Shyra J},
  title = {SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2023},
  doi = {10.1136/jitc-2023-007572}
}
Kostenlos starten →